The potential acquisition of Syqe Medical by Phillip Morris represents a significant strategic move for the tobacco giant, signaling its entry into the flourishing marijuana industry. With an initial investment of $130 million to support Syqe’s FDA approval process, followed by a possible $650 million acquisition, this deal can potentially make Syqe one of the largest cannabis companies globally. Moreover, Syqe’s innovative inhaler, utilizing raw cannabis inflorescence, could secure FDA approval, positioning the company as a trailblazer in the medical cannabis sector.
Germany has received nearly 900 applications for cannabis cultivation associations, but only just over half…
A Senate stopgap funding bill would delay the federal prohibition on most hemp-derived THC products…
He smokes in boardrooms, but he’s still on that underground frequency. This content originally appeared…
Fox News opinion ran a piece recently from Scott Chipman, vice president of Americans Against…
For our 50th anniversary, we handed the plant to the artists making its most striking…
Corporate valuation increased in 21 of the 38 states studied following medical marijuana legalization. Gross…